BioNTech to Shutter Sites in Germany, Singapore as No Buyers Emerge
The restructuring affects about 1,800 jobs as BioNTech shifts COVID-19 vaccine production to Pfizer and seeks annual savings of about $587 million.
- On Monday, September 28, 2026, BioNTech announced it will close three German sites in Marburg, Idar-Oberstein, and Tübingen after failing to secure buyers for the facilities.
- Following an unsuccessful, wide-ranging sales process, BioNTech is pivoting away from pandemic-era vaccine manufacturing to focus on other priorities amid declining COVID-19 demand.
- Restructuring efforts affect up to 1,860 jobs across the three sites, though BioNTech reached agreements with its works council on supplementary redundancy terms for affected employees.
- BioNTech estimates the restructuring could eventually generate annual savings of around $587 million while redirecting resources toward its oncology pipeline and other ventures.
- Beyond the restructuring, BioNTech's two co-founders plan to depart by year-end to launch a new venture, signaling broader leadership transition within the company.
59 Articles
59 Articles
The German manufacturer of vaccines against Covid-19 BioNTech said, on Monday (28), that it will close units in Germany that did not manage to sell, as it moves away from the production structure assembled during the pandemic. Despite the best efforts of all involved and a wide sales process, unfortunately it was not possible to conclude a transaction, said a spokesman. The spokesman added that the biotechnology company reached an agreement with…
Protothema
The company will close its units in the cities of Tübingen, Marburg and Idar Oberstein - Impact on 1,800 jobs
Leaded by the decline in demand for its Covid-19 vaccine and the absence of new commercial products, the German biotech BioNTech is about to close three sites in the country, threatening 1,800 jobs. ...
1800 employees could lose their job because no buyer was found for the three plants. The pharmaceutical company is in a veritable crisis.
Coverage Details
Bias Distribution
- 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
